Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Platinum for Triple-Negative Metastatic Breast Cancer and Evaluation of p63/p73 as a Biomarker of Response

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified November 2014 by Massachusetts General Hospital.
Recruitment status was:  Active, not recruiting
Sponsor:
Collaborators:
Beth Israel Deaconess Medical Center
Dana-Farber Cancer Institute
North Shore Medical Center
Information provided by (Responsible Party):
Steven Isakoff, MD, PhD, Massachusetts General Hospital
ClinicalTrials.gov Identifier:
NCT00483223
First received: June 5, 2007
Last updated: November 10, 2014
Last verified: November 2014
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is ongoing, but not recruiting participants.
  Estimated Study Completion Date: December 2016
  Primary Completion Date: June 2014 (Final data collection date for primary outcome measure)
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):